Table 8. Intermediate health outcomes (2)

| Study, year | Study group | Followup | PASI50 n/N | PASI75 n/N | PASI90 n/N | PASI100 n/N | PASImean(SD) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| CT5, 2012 | Etanercept | 2w4w8w12w18w24w | 1/2110/2115/2116/2116/2115/21 | ---------------11/21 | ------------------ | ------------------ | -5.38(7.13)\*-9.98(10.64)\*-11.11(10.89)\*-11.97(11.63)\*-12.13(11.67)\*-12.16(12.15)\* |
|  | Acitretin | 2w4w8w12w18w24w | 0/182/185/184/187/188/18 | ---------------4/18 | ------------------ | ------------------ | -3.17(5.60)\*-4.06(5.68)\*-6.84(9.57)\*-6.71(6.81)\*-8.77(8.54)\*-9.62(10.10)\* |
| Gelfand, 2012 | MTX | --- | --- | --- | --- | --- | 3.8(1.8 to 6.6)† |
|  | Adalimumab | --- | --- | --- | -- | --- | 2.5(1.2 to 4.8)† |
|  | Etanercept | --- | --- | --- | --- | --- | 2.9(1.8 to 4.9)† |
|  | Ustekinumab | --- | --- | --- | --- | --- | 4.0(1.0 to 7.9)† |
|  | NB-UVB | --- | --- | --- | --- | --- | 3.5(2.0 to 5.5)† |
| Barker, 2011 | Infliximab | 2w6w10w14w16w18w‡22w‡26w‡ | 247/653535/653579/653562/653567/653543/653530/653529/653 | 59/653365/653487/653473/653508/653488/653473/653502/653 | 11/653150/653291/653310/653356/653349/653306/653333/653 | ------------------------ | -------------------85%§ |
|  | MTX | 2w6w10w14w16w18w‡22w‡26w‡ | 19/21580/215118/215131/215130/215120/215118/215103/215 | 1/21531/21558/21585/21590/21585/21582/21566/215 | 0/2156/21519/21537/21541/21539/21539/21532/215 | ------------------------ | ----------------------54%§ |
|  | Infliximab transitioned to MTX | 18w22w26w | --------- | 0/91/91/9 | 0/90/90/9 | --------- | --------- |
|  | MTX transitioned to infliximab | 18w22w26w | --------- | 15/6338/6346/63 | 5/6317/6330/63 | --------- | --------- |
| Emerit, 2011 | Etanercept | 0w12w32w | --------- | --------- | --------- | --------- | 21.4(6.1)3.7(1.2)--- |
|  | Infliximab | 0w12w32w | --------- | --------- | --------- | --------- | 22.3(6.5)2.1(0.7)--- |
|  | PUVA | 0w12w32w | --------- | --------- | --------- | --------- | 21.9(6.3)2.2(1.1)7.3(1.8) |
|  | NB-UVB | 0w12w32w | --------- | --------- | --------- | --------- | 21.3(5.2)3.7(1.2)10.8(2.2) |
| Inzinger, 2011|| | Adalimumab | 12w | 13/18 | 10/18 | 4/18 | 1/18 | --- |
|  | Alefacept | 12w | 20/32 | 8/32 | 1/32 | 1/32 | --- |
|  | Etanercept | 12w | 32/38 | 15/38 | 11/38 | 2/38 | --- |
|  | Infliximab | 12w | 7/7 | 7/7 | 5/7 | 2/7 | --- |
|  | Ustekinumab | 12w | 16/18 | 12/18 | 7/18 | 1/18 | --- |
|  | PUVA | 10.3w¶ | 65/71 | 63/71 | 50/71 | 15/71 | --- |
| Strober, 2011 | MTX transitioned to adalimumab | 0w2w4w8w16w | --------------- | --------------- | --------------- | --------------- | 10.8(NR)6.9(NR)5.4(NR)3.4(NR)2.3(NR) |
|  | NB-UVB transitioned to adalimumab | 0w2w4w8w16w | --------------- | --------------- | --------------- | --------------- | 12.4(NR)9.1(NR)6.7(NR)4.1(NR)3.6(NR) |
| Garavaglia, 2010 | CyA transitioned to etanercept | --- | --- | --- | --- | --- | --- |
| Caproni, 2009 | Etanercept | 12w | 26/30 | 17/30 | --- | --- | 4.61(2.75) |
|  | Acitretin | 12w | 20/30 | 8/30 | --- | --- | 9.62(4.64) |
| Mazzotta, 2009 | Nonbiologics or phototherapy transitioned to etanercept\*\* | 12w24w | 79/9888/98 | 43/9874/98 | ------ | ------ | 4.9(4.0)2.8(3.4) |
| Gisondi, 2008a | Etanercept | 6w12w18w24w | 6/229/2211/2215/22 | 2/225/228/2210/22 | ------------ | ------------ | ------------ |
|  | Acitretin | 6w12w18w24w | 2/204/207/2010/20 | 1/202/202/206/20 | ------------ | ------------ | ------------ |
| Gisondi, 2008b | Etanercept | 24w | --- | --- | --- | --- | 4.8(4.7)-74.5%§ |
|  | Infliximab | 24w | --- | --- | --- | --- | 2.1(3.2)-88.8%§ |
|  | MTX | 24w | --- | --- | --- | --- | 4.3(6.0)-47.1%§ |
| Saurat, 2008 | Adalimumab | 2w4w8w12w16w | ---73/10888/10898/10895/108 | 5/10825/10867/10883/10886/108 | ---7/10829/10852/10856/108 | ---1/1089/10812/10818/108 | -------------16.7(8.8)\* |
|  | MTX | 2w4w8w12w16w | ---17/11042/11060/11068/110 | 0/1103/11010/11027/11039/110 | ---1/1103/11010/11015/110 | ---1/1100/1101/1108/110 | -------------10.9(8.3)\* |
|  | MTX transitioned to adalimumab  | 0w24w | ------ | 26/9570/95 | 13/9550/95 | 5/9530/95 | ------ |
| Magliocco, 2007 | CyA transitioned to alefacept | --- | --- | --- | --- | --- | --- |
| Costanzo, 2005 | Nonbiologics transitioned to etanercept†† | 12w24w | 28/4412/15 | 19/4410/15 | 4/446/15 | ------ | 7.5(NR)-52%§4.3(NR)-72%§ |

Abbreviations: CyA=cyclosporine; MTX=methotrexate; n/N=number of patients per total population; NB-UVB=narrowband ultraviolet B; NR=not reported; PASI=Psoriasis Area and Severity Index; PUVA=psoralen plus ultraviolet A; w=week(s); ---=not reported

\* Mean(SD) change from baseline

† Median (IQR)

‡ Includes patients who switched treatments at week 16 as nonresponders

§ Mean percentage change from baseline

|| Results reported out of treatment courses, not patients. Patients could have more than one treatment course

¶ End of phototherapy treatment, median 10.3w

\*\* Nonbiologics included CyA, corticosteroids, MTX, retinoids

†† Nonbiologics included CyA, corticosteroids, fumaric acid esters, MTX, retinoids, PUVA